Dr Paul Auwaerter addresses some misunderstandings about the management of Clostridium difficile infection that he discovered during his time on a consultation service.

Dr John Buse highlights some of the new drugs and devices being developed for type 2 and type 1 diabetes.

We know that insulin can help patients with diabetes, but can it also place them in harm's way?

We are starting to lose our last line of defense against drug-resistant gonorrhea. What can be done?

Dr Andrew Kaunitz describes results of a recent population-based study that supports the 'critical window' hypothesis of hormone therapy after menopause.

Dr Peter Yellowlees talks about clozapine vs first- and second-generation antipsychotics in treatment-refractory schizophrenia.

How can we address patients' fears about insulin? Dr Shubrook speaks with Dr Jim LaSalle about the benefits of earlier use of insulin in patients with type 2 diabetes.

Drs Shubrook and Skolnik discuss the role of GLP-1 receptor agonists in the management of type 2 diabetes and the surprising benefits of these agents when combined with insulin.

Stuart Pocock reviews 12 key considerations when the outcome of a clinical trial is negative, using familiar trials to illustrate these points. Can the data be salvaged, or is it a 'no-hoper'?

The FDA's recent addition of a cardiovascular indication for diabetes drug empagliflozin is a significant milestone in diabetes care, says Dr Anne Peters.